iShares U.S. Healthcare ETFIYH

The iShares U.S. Healthcare ETF (IYH) is sold as a high-octane sprint into the future of medicine, where algorithms and breakthroughs collide in a blaze of investor glory. In reality, it’s a $8.3 billion spreadsheet that tracks the Dow Jones U.S. Select Healthcare Provision Index, a benchmark so stodgy it could double as a filing trail stack. The fund’s top holdings-UnitedHealth Group (7.8%), Thermo Fisher Scientific (5.2%), and Merck (4.9%)-are the healthcare equivalent of a retirement home: reliable, dividend-paying, and allergic to genuine disruption. The issuer’s own product pages promise "AI’s potential growth and innovation," but the portfolio reads like a 2012 Yahoo Finance screener. The fund’s expense ratio is 0.42%, which is cheaper than many active funds but still a toll you pay to own a basket of stocks you didn’t pick and can’t relative strength.

BlackRock’s marketing machine dresses this up as a theme park ride-complete with aerials of multi-level highways and images of machinery-but the fine print is a warning that most UK regulatory protections don’t apply to iShares products. The fund’s disclaimers explicitly state that compensation will not be available under the UK Financial Services Compensation Scheme in the event of default, meaning investors are on their own if the wrapper cracks. The fund’s liquidity is robust, with average daily volume over 200,000 shares, but that liquidity is a feature of the wrapper, not the underlying stocks. The fund’s holdings are updated quarterly, which means the "cutting-edge" promise is really just a committee updating a list of stocks every few months.

The fund’s mandate is to track the Dow Jones U.S. Select Healthcare Provision Index, a benchmark so tightly defined it feels less like a map of the future and more like a filing trail stack of legacy healthcare stocks. The fund’s top ten holdings account for nearly 60% of the portfolio, meaning your "diversified" exposure is really a bet on a handful of giant firms whose fortunes rise and fall with Washington’s latest healthcare policy or FDA whim. The issuer’s own product pages promise "expert management" and "industry-leading research," but the index’s composition suggests the research has already been done-and it’s just a list of names you could have bought on Yahoo Finance in 2012. The fund’s expense ratio of 0.42% is the toll road you pay to avoid picking stocks yourself, while the issuer’s disclaimers warn that the protections usually provided by the UK system are absent.

For those who want to see where IYH trades, the Nasdaq market activity page shows the fund’s liquidity and recent price action, but remember: the chart you see is a wrapper around a basket of stocks, not a story of healthcare revolution. The fund’s performance is tied to the index it tracks, which is updated quarterly, meaning the "cutting-edge" stocks you own today might be tomorrow’s has-beens. The issuer’s own literature warns that the fund’s performance is tied to the index’s rules, which are set by S&P Dow Jones Indices-a committee, not a crystal ball. If you’re after thematic disruption, this fund is the healthcare equivalent of a horse-drawn ambulance: functional, but not what the brochure promised.

The fund’s regulatory filings reveal that it is a Delaware statutory trust, a legal shell designed to hold stocks and charge fees, not a company that makes anything. The fund’s expense ratio is 0.42%, which is lower than some active funds but higher than the dirt-cheap S&P 500 ETFs that charge 0.03%. The fund’s holdings are disclosed quarterly, but the issuer’s own warnings make clear that investors are on the hook for any regulatory or tax surprises. The fund’s marketing still uses images of machinery and aerials, but the reality is a static portfolio of stocks that change only when the index changes. The issuer’s disclaimers explicitly state that most of the protections provided by the UK regulatory system do not apply to the operation of the iShares products.

What changed this week? Not much in the fund’s holdings, which are updated only when the index is rebalanced. The fund’s expense ratio remains 0.42%, and its AUM sits at $8.3 billion, a figure that sounds impressive until you remember the issuer’s warnings about regulatory protections. The fund’s liquidity is robust, but that’s a feature of the wrapper, not the underlying stocks. The issuer’s own product pages still promise "AI’s potential growth and innovation," but the portfolio is still dominated by firms that would struggle to explain what they do with a whiteboard, let alone a neural network. If you’re after genuine disruption, this fund is the healthcare equivalent of a horse-drawn ambulance: functional, but not what the brochure promised.

The evidence here is thin on fundamental shifts in the fund’s holdings or mandate, but rich in issuer marketing and fee extraction. The fund’s top holdings are still the same old guard: UnitedHealth Group, Thermo Fisher Scientific, and Merck, which have been paying dividends since before smartphones. The fund’s expense ratio of 0.42% is the toll you pay to own a basket of stocks you didn’t pick and can’t relative strength. The issuer’s disclaimers warn that most UK regulatory protections don’t apply to iShares products, so if the fund’s basket implodes, you’re on your own. The fund’s performance is tied to the index it tracks, which is updated quarterly, meaning the "cutting-edge" promise is really just a committee updating a list of stocks every few months. The fund’s liquidity is robust, but that liquidity is a feature of the wrapper, not the underlying stocks.